Mini-GRID radiotherapy limited senescence in rat glioma cells while killing them comparably
Thumbnail from YouTube. Playing loads the YouTube player.
History & recommendationsOff
Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.
Open saved items & history →At a glance
Automatic summary · not editorially reviewedIn the described study, mini-GRID radiotherapy reduced senescence and SASP signals in two rat glioma cell lines compared with conventional radiotherapy at 20 Gy while achieving comparable cell number reduction; in astrocytes and mouse fibroblasts, senescence rose with dose and did not differ between modalities. [1]
In the glioma cell lines F98 and RG2, conventional radiotherapy at 20 Gy induced a strong senescent phenotype, while mini-GRID radiotherapy achieved comparable cell number reduction while limiting senescence and SASP activation. [1]
The description concludes that mini-GRID radiotherapy maintained the cytotoxic effectiveness of conventional irradiation in glioma cells while reducing senescence and SASP induction, supporting further investigation. [1]
In astrocytes and mouse embryonic fibroblasts, radiation induced senescence dose-dependently, with no significant differences between irradiation modalities. [1]
Senescence after mini-GRID versus conventional radiation
The description reports an in vitro study comparing single radiation doses of 5 to 20 Gy delivered as conventional radiotherapy or mini-GRID radiotherapy. Seven days after irradiation, senescence was assessed by SA-β-galactosidase activity and cell size, with markers p53, p21 and p16 and SASP-related genes also measured. In the glioma lines F98 and RG2, conventional radiotherapy at 20 Gy produced a strong senescent phenotype: larger cells, higher SA-β-Gal activity, persistent DNA damage signaling and upregulation of p53, p21, p16 and SASP genes. Mini-GRID radiotherapy achieved comparable cell number reduction while limiting senescence, DNA damage signaling and SASP activation, with expression approaching non-irradiated controls. [1]
Astrocytes and mouse fibroblasts: dose-dependent senescence, no modality difference
In immortalized astrocytes (CTX-TNA2) and primary mouse embryonic fibroblasts, the description states that radiation induced senescence in a dose-dependent manner, with no significant differences between the two irradiation modalities. This contrasts with the glioma cell lines, where the modalities differed in senescence induction. The description does not report how normal-cell survival or other outcomes compared between modalities. [1]
What the described findings do and do not show
The description concludes that mini-GRID radiotherapy maintained the cytotoxic effectiveness of conventional irradiation in glioma cells while reducing senescence and SASP induction, and calls this a potential to improve the therapeutic ratio that supports further investigation. These are cell-culture results, not evidence of benefit in patients or of effects on lifespan. The description gives no information on animal models, human participants, follow-up or clinical outcomes, and the video and transcript were not reviewed. [1]
Context & limits
This is a video description of an abstract; the video and transcript were not reviewed. Results come from cell lines and primary mouse fibroblasts in culture, not from patients or animal models, and the description reports no clinical outcomes or follow-up.
Based on the creator’s description; the full video and transcript were not analyzed.
Quoted passages in the original language
achieved comparable cell number reduction while significantly
maintains the cytotoxic effectiveness of conventional irradiation
radiation induced senescence in a dose-dependent manner
About this video
Creator description · original textText language: English
Aging Journal · 2 min · Source published: 2026-10-05
Added to Harbor: 10/23/2026
Original on YouTube ↗Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.